Current Edition

cancer

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

 Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced …

Continue Reading →